Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 469-480 , May 2006

Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein

  • Vladimir S. Talanov

      Affiliations

    • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    • Corresponding Author InformationCorresponding authors. Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Institutes of Health, Bethesda, MD 20892-1002, USA.
    • Current affiliation: Department of Chemistry, Howard University, 525 College St. NW, Washington, DC 20059, USA.
    • ,
  • Kayhan Garmestani

      Affiliations

    • Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Celeste A.S. Regino

      Affiliations

    • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Diane E. Milenic

      Affiliations

    • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Paul S. Plascjak

      Affiliations

    • Department of Nuclear Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Thomas A. Waldmann

      Affiliations

    • Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Martin W. Brechbiel

      Affiliations

    • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    • Corresponding Author InformationCorresponding authors. Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Institutes of Health, Bethesda, MD 20892-1002, USA.

Received 16 October 2005 ,Revised 26 February 2006 ,Accepted 5 March 2006.

References 

  1. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol. 2001;2:341–349
  2. Pandit-Taskar N, Hamlin PA, Reyes S, Larson SM, Divgi CR. New strategies in radioimmunotherapy for lymphoma. Curr Oncol Rep. 2003;5:364–371
  3. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with 131I-anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459–465
  4. Knox SJ, Goris ML, Trisler K, Negrim R, Davis T, Liles T-M, et al. Yttrium-90-labeled anti-CD20 Monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–470
  5. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet. 1995;346:336–340
  6. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063–4075
  7. Zhang M, Yao Z, Garmestani K, Axworthy D, Zhang Z, Mallett B, et al. Pretargeting radioimmunotherapy of a murine model of adult T cell leukemia (ATL) with the alpha emitting radionuclide, Bi-213. Blood. 2002;100:208–216
  8. Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, et al. Pretarget radioimmunotherapy provides effective treatment for lymphoma and leukemia xenografts. Proc Natl Acad Sci U S A. 2003;100:1891–1895
  9. Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and 90Y-DOTA-biotin. Cancer Res. 2002;62:5755–5760
  10. Dadachova E, Nakouzi A, Bryan RA, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A. 2003;100:10942–10947
  11. Miederer M, Seidl C, Beyer G, David E, Charlton DE, Vranjes-Duric S, et al. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Rad Res. 2003;159:612–620
  12. Henriksen G, Breistøl K, Bruland OS, Fodstad Ø, Larsen RH. Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–3125
  13. Jurcic JG, Caron PC, Scheinberg DA. Monoclonal antibody therapy of leukemia and lymphoma. In:  August JT,  Anders MW,  Murad F,  Coyle JT editor. Advances in pharmacology. vol. 33:New York: Academic Press, Inc.; 1995;p. 287–314
  14. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  15. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75–83
  16. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341–1351
  17. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Design. 2000;6:1433–1455
  18. Milenic DE, Brady ED, Brechbiel MW. Antibody targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3:488–498
  19. Aaij C, Tschroots WRJM, Lindner L, Feltkamp TEW. The preparation of astatine labelled proteins. Int J Appl Radiat Isot. 1975;26:25–30
  20. Vaughan ATM, Fremlin JH. The preparation of astatine labelled proteins using an electrophilic reaction. Int J Nucl Med Biol. 1978;5:229–230
  21. Garg PK, Harrison CL, Zalutsky MR. Comparative tissue distribution in mice of the α-emitter 211At and 131I as labels of a monoclonal antibody and F(ab′)2 fragment. Cancer Res. 1990;50:3514–3520
  22. Garg PK, Garg S, Zalutsky MR. N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. Nucl Med Biol. 1993;20:379–387
  23. Harrison A, Royle L. Preparation of a 211At–IgG conjugate which is stable in vivo. Int J Appl Radiat Isot. 1984;35:1005–1008
  24. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab′)2 fragments with the α-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci U S A. 1989;86:7149–7153
  25. Zalutsky MR, Stabin MG, Larsen RH, Bigner DD. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate. Nucl Med Biol. 1997;24:255–261
  26. Yordanov AT, Garmestani K, Phillips KE, Herring B, Horak E, Beitzel MP, et al. Preparation and in vivo evaluation of linkers for 211At labeling of humanized Anti-Tac. Nucl Med Biol. 2001;28:845–856
  27. Talanov VS, Yordanov AT, Garmestani K, Milenic DE, Arora HC, Plascjak PS, et al. Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins. Nucl Med Biol. 2004;31:1061–1071
  28. Schwarz UP, Plascjak P, Beitzel MP, Gansow OA, Eckelman WC, Waldmann TA. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. Nucl Med Biol. 1998;25:89–93
  29. De Darlo F, Ranzi G. 2-Methylisoxazolin-5-ones. Part II: ring-opening by bases. Tetrahedron. 1966;22:2995–2999
  30. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol. 2002;29:599–606
  31. Tom RH, Rutzky LH, Jakstys MH. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro. 1976;12:180–191
  32. Colcher D, Keenan AM, Larson SM, Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res. 1984;44:5744–5781
  33. Safavy A, Georg GI, Velde DV, Raisch KP, Safavy K, Carpenter M, et al. Site-specifically traced drug release and biodistribution of a paclitaxel–antibody conjugate toward improvement of the linker structure. Bioconjugate Chem. 2004;15:1264–1274

PII: S0969-8051(06)00039-4

doi: 10.1016/j.nucmedbio.2006.03.001

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 469-480 , May 2006

Article Tools

* Image Usage & Resolution